 
Gas for VMT v3.0 7 -24-19           
     
DRCR Retina Network  
 
 
 
 
Randomized Clinical Trial Assessing the 
Effects of Pneumatic Vitreolysis on 
Vitreomacular Traction   
(Protocol A G) 
 
 
IDE Sponsor : Jaeb Center for Health Research  (JCHR)  
 
Version 3.0 
 
24 July 2019  
 
NCT0364726 7 
 
 
Gas for VMT v3.0 7 -24-19           
    Signature Page  
Randomized Clinical Trial Assessing the Effects of 
Pneumatic Vitreolysis on Vitreomacular Traction  
Protocol Identifying Number: DRCR Retina Network  AG 
IDE Sponsor: Jaeb Center for Health Research  
Version Number: 3.0 
24 July 2019  
 
 
 
JCHR Principal Investigator   
Name, degree  Adam Glassman, MS  
 
Signature / Date   
 
 
 
 
 
 
 
Jaeb Center for Health Research  
Gas for VMT v3.0 7 -24-19           
    KEY ROLES  
 
Protocol Chair   
Name, degree  Clement K. Chan, MD, FACS  
Title  Medical Director  
Institution Name  Southern California Desert Retina Consultants, Palm Desert, CA  
 
JCHR Coordinating Center Director   
Name, degree  Adam Glassman, MS  
Title  Director  of DRCR Retina Network  Coordinating Center  
Institution Name  Jaeb Center for Health Research , Tampa, FL  
 
Network Chair   
Name, degree  Daniel F. Martin, MD  
Title  Chairman, Cole Eye Institute  
Institution Name  Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio  
 
Medical Monitor   
Name, Title  Robert Lindblad, Senior Medical Officer  
Ashraf El Fiky, Medical Officer  
Institution Name  The EMMES Corporation  
Jaeb Center for Health Research  
Gas for VMT v3.0 7 -24-19           
    TABLE OF CONTENTS  
Chapter 1:  Background Information and Study Synopsis  ................................ ..........................  1-1 
1.1. Introduction  ................................ ................................ ................................ ...................  1-1 
1.1.1 Vitreoretinal Interface Abnormalities  ................................ ................................ .........  1-1 
1.1.2 Treatments for VMT  ................................ ................................ ................................ ... 1-1 
1.1.3 Pneumatic Vitreolysis (PVL)  ................................ ................................ ......................  1-2 
1.2. Rationale  ................................ ................................ ................................ ........................  1-2 
1.3 Study Objectives  ................................ ................................ ................................ ...........  1-2 
1.4 Potential Risks and Benefits of C 3F8 Gas Injection  ................................ .......................  1-3 
1.4.1 Known Potential Risks  ................................ ................................ ................................  1-3 
1.4.2 Known Potential Benefits  ................................ ................................ ...........................  1-4 
1.4.3 Risk Assessment  ................................ ................................ ................................ .........  1-4 
1.5 General Considerations  ................................ ................................ ................................ . 1-4 
Chapter 2:  Study Participant Eligibility and Enrollment  ................................ ...........................  2-1 
2.1 Randomized Trial Participant Recruitment and Enrollment  ................................ ..............  2-1 
2.2 Participant Eligibility Criteria  ................................ ................................ ............................  2-1 
2.2.1 Participant -level Criteria  ................................ ................................ .............................  2-1 
2.2.2 Study Eye Criteria  ................................ ................................ ................................ ....... 2-2 
2.3 Screening Evaluation and Baseline Testing  ................................ ................................ ....... 2-4 
2.3.1 Baseline Testing Procedures  ................................ ................................ .......................  2-4 
2.4 Randomization of Eligible Participants  ................................ ................................ .............  2-5 
Chapter 3:  Baseline Treatment  ................................ ................................ ................................ ... 3-1 
3.1 Treatment  ................................ ................................ ................................ ...........................  3-1 
3.2 Injection Procedure  ................................ ................................ ................................ ............  3-1 
3.2.1 Intravitreous Injection Technique  ................................ ................................ ...............  3-1 
3.2.2 Aqueous Sample Collection  ................................ ................................ ........................  3-1 
3.2.3 Sham Injection Technique  ................................ ................................ ..........................  3-1 
3.3 Participant Instructions Post -Injection  ................................ ................................ ...............  3-1 
Chapter 4:  Follow -Up Visits and Testing  ................................ ................................ ..................  4-1 
4.1 Study Visits  ................................ ................................ ................................ ........................  4-1 
4.1.1 Procedures at Study Visits  ................................ ................................ ..........................  4-1 
4.1.2 Unscheduled Visits  ................................ ................................ ................................ ..... 4-1 
4.2 Treatment During Follow -Up ................................ ................................ ............................  4-2 
4.2.1 Criteria for Vitrectomy  ................................ ................................ ...............................  4-2 
Jaeb Center for Health Research  
Gas for VMT v3.0 7 -24-19           
    4.2.2 Treatment for Other Conditions in the Study Eye  ................................ ......................  4-2 
4.2.3 Treatment in the Non -Study Eye  ................................ ................................ ................  4-2 
Chapter 5:  Study Device  ................................ ................................ ................................ ............  5-1 
5.2 Study Device Accountability Procedures  ................................ ................................ ..........  5-1 
5.3 Safety Measures  ................................ ................................ ................................ .................  5-1 
Chapter 6:  Adverse Events, Device Issues, and Stopping Rules  ................................ ...............  6-1 
6.1 Adverse Events  ................................ ................................ ................................ ..................  6-1 
6.1.1 Definitions ................................ ................................ ................................ ...................  6-1 
6.1.2 Reportab le Adverse Events  ................................ ................................ .........................  6-2 
6.1.3 Relationship of Adverse Event to Study Device ................................ .........................  6-2 
6.1.4 Intensity of Adverse Event ................................ ................................ ..........................  6-2 
6.1.5 Coding of Adverse Events  ................................ ................................ ..........................  6-3 
6.1.6 Outcome of Adverse Event  ................................ ................................ .........................  6-3 
6.2 Reportable Device Issues  ................................ ................................ ................................ ... 6-4 
6.3 Pregnancy Reporting  ................................ ................................ ................................ ..........  6-4 
6.4 Timing of Event Reporting  ................................ ................................ ................................  6-4 
6.5 Stopping Criteria  ................................ ................................ ................................ ................  6-4 
6.5.1 Criteria for Suspending or Stopping Overall Study  ................................ ....................  6-4 
6.6 Independent Safety Oversight  ................................ ................................ ............................  6-5 
6.7 Risks  ................................ ................................ ................................ ................................ ... 6-5 
Chapter 7:  Miscellaneous Considerations  ................................ ................................ ..................  7-1 
7.1 Prohibited Medications, Treatments, and Procedures  ................................ ........................  7-1 
7.2 Participant Withdrawal  ................................ ................................ ................................ ...... 7-1 
7.3 Discontinuation of Study  ................................ ................................ ................................ ... 7-1 
7.4 Confidentiality  ................................ ................................ ................................ ...................  7-1 
7.5 Particip ant Compensation  ................................ ................................ ................................ .. 7-1 
Chapter 8:  Statistical Considerations  ................................ ................................ .........................  8-1 
8.1 Statistical and Analytical Plans  ................................ ................................ ..........................  8-1 
8.2 Statistical Hypotheses  ................................ ................................ ................................ ........  8-1 
8.3 Sample Size  ................................ ................................ ................................ ........................  8-1 
8.3.1 Outcome Projections:  ................................ ................................ ................................ .. 8-1 
8.3.2 Sample Size Estimates  ................................ ................................ ................................  8-1 
8.4 Outcome Measures ................................ ................................ ................................ .............  8-2 
8.5 Analysis Cohorts  ................................ ................................ ................................ ................  8-3 
Jaeb Center for Health Research  
Gas for VMT v3.0 7 -24-19           
    8.6 Analysis  of the Primary Efficacy Outcome  ................................ ................................ ....... 8-3 
8.7 Analysis of the Secondary and Exploratory Efficacy Outcomes  ................................ ....... 8-4 
8.8 Safety Analyses  ................................ ................................ ................................ ..................  8-5 
8.8.1 Ocular Adverse Events  ................................ ................................ ...............................  8-5 
8.8.2 Systemic Adverse Events  ................................ ................................ ............................  8-6 
8.9 Intervention Adherence  ................................ ................................ ................................ ...... 8-6 
8.10 Protocol Adherence and Retention  ................................ ................................ ..................  8-6 
8.11 Baseline Descriptive Statistics  ................................ ................................ .........................  8-6 
8.12 Planned Interim Analyses  ................................ ................................ ................................  8-6 
8.13 Subgroup Analyses  ................................ ................................ ................................ ..........  8-6 
8.14 Multiple Testing  ................................ ................................ ................................ ...............  8-7 
8.15 Assessment of Confounding  ................................ ................................ ............................  8-7 
Chapter 9:  Data Collection and Monitoring  ................................ ................................ ...............  9-1 
9.1 Case Report Forms and Device Data  ................................ ................................ .................  9-1 
9.2 Study Records Retention ................................ ................................ ................................ .... 9-1 
9.3 Quality Assurance and Moni toring  ................................ ................................ ....................  9-1 
9.4 Protocol Deviations  ................................ ................................ ................................ ............  9-2 
Chapter 10:  Ethics/Protection of Human Participants  ................................ .............................  10-1 
10.1 Ethical Standard  ................................ ................................ ................................ .............  10-1 
10.2 Institutional Review Boards  ................................ ................................ ...........................  10-1 
10.3 Informed Consent Process  ................................ ................................ .............................  10-1 
10.3.1 Consent Procedures and Documentation  ................................ ................................  10-1 
10.3.2 Participant and Data Confidentiality  ................................ ................................ ....... 10-1 
10.3.3 Future Use of Stored Specimens  ................................ ................................ .............  10-2 
Chapter 11:  References  ................................ ................................ ................................ ............  11-1 
 
 
 
 
 
 
 
 
 
 
  
 
JAEB CENTER FOR HEALTH RESEARCH  
Gas for VMT v3.0 7 -24-19           
    LIST OF ABBREVIATIONS  
ABBREVIATION  DEFINITION  
AUC  Area Under the Curve  
CI Confidence Interval  
CRF  Case Report Form  
DSMC  Data and Safety Monitoring Committee  
E-ETDRS  Electronic -Early Treatment Diabetic Retinopathy Study  
ERM  Epiretinal Membrane  
ETDRS  Early Treatment Diabetic Retinopathy Study  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
ICH International Conference on Harmonization   
ID Identification  
IDE Investigational Device Exemption  
IOP Intraocular Pressure  
IRB Institutional Review Board  
ITT Intention -to-Treat  
JCHR  Jaeb Center for Health Research  
MH Macular Hole  
OCT  Optical Coherence Tomography  
PVD  Posterior Vitreous Detachment  
PVL  Pneumatic Vitreolysis  
SADE  Serious Adverse Device Event  
SAE  Serious Adverse Event  
SDH  Shape Discrimination Hyperacuity  
SD Standard Deviation  
UADE  Unanticipated Adverse Device Effect  
VMT  Vitreomacular Traction  
VMA  Vitreomacular Adhesion  
 
JAEB CENTER FOR HEALTH RESEARCH  
Gas for VMT v3.0 7 -24-19           
    PROTOCOL SUMMARY  
PARTICIPANT AREA  DESCRIPTION  
Title  Randomized Clinical Trial Assessing the Effects of 
Pneumatic Vitreolysis on Vitreomacular Traction  
Précis  Eyes with idiopathic symptomatic vitreomacular traction 
(VMT) without a macular hole will be randomly assigned to 
0.3-mL intraocular gas  (C3F8) injection or sham injection to 
determine if pneumatic vitreolysis (PVL) is effective in 
releasing VMT . 
Investigational Device  0.3-mL intraocular gas (C 3F8) injection  
Objectives  Primary  
1. To compare the proportion of eyes with central  
VMT  release on OCT after pneumatic vitreolysis 
with gas injection versus observation (sham  
injection ) in eyes with VMT  without an associated 
macular hole .  
Secondary  
2. To evaluate visual function outcomes at 24 weeks 
after gas injection is performed compared with sham 
injection .  
Study Design  Multi -center , randomized  clinical trial  
Number of Sites  Approximately 50 sites  
Endpoint  Primary Outcome:  Proportion  of eyes with central  VMT 
release  on optical coherence tomography ( OCT ) without 
rescue treatment  at 24 weeks . 
 
Key Secondary Outcomes: Proportion of eyes with rescue 
treatment, mean change in visual acuity  
 
Key Safety Outcomes: Retinal tear, retinal detachment, 
macular hole development,  traumatic cataract,  cataract  
extraction , vitreous  hemorrhage, intraocular press ure (IOP)  
increase,  and endophthalmitis . 
Population  Key Inclusion Criteria  
• Age ≥18 years.  
• Able and willing to avoid high altitude travel until 
gas resolution (approximately 6 to 8 weeks ).  
• For phakic patients, a ble and willing to avoid supine 
positioning  until gas resolution  (approximately 6 to 
8 weeks) . 
• At least one eye with  each of the following : 
JAEB CENTER FOR HEALTH RESEARCH  
Gas for VMT v3.0 7 -24-19           
    PARTICIPANT AREA  DESCRIPTION  
o central vitreomacular adhesion  on OCT that is 
no larger than 3000 microns , confirmed by 
central reading center , 
o decreased visual function (e.g. metamorphopsia 
or other visual symptom) that is attributed to 
VMT ,  
o best corrected Early Treatment Diabetic 
Retinopathy Study ( ETDRS ) visual acuity 
equivalent of 20/ 32 to 20/400 , and  
o prompt vitrectomy not required  
Key Exclusion Criteria  
• Macular or lamellar hole . 
• Other condition that might affect visual acuity 
during the course of the study (e.g. retinal vein 
occlusion , advanced age-related macular 
degeneration , or macular edema induced by a 
condition other than VMT) . 
o Note: Epiretinal membrane is not  an 
exclusion nor a requirement.  
• High level myopia ( -8.00 diopters or more  negative 
if phakic; retinal abnormalities consistent with 
pathologic myopia if phakic or pseudophakic ). 
• Prior gas injection, ocriplasmin injection, or 
intraocular injection for any  reason . 
• Prior vitrectomy . 
Sample Size  Minimum of 124 eyes 
Treatment Groups  Random assignment (1:1) to one of the following:  
Group A: PVL ( 0.3-mL C 3F8 injection ) 
Group B: Observation  (Sham injection ) 
Participant Duration  24 weeks  
Protocol 
Overview/Synopsis  1. Informed consent will be obtained for screening.  
2. Eligibility will be assessed, including reading center 
confirmation of VMT  on OCT .  
3. Eligible eyes will be randomly assigned to C 3F8 
injection (0.3  mL) or sham  injection , which will be 
performed on the day of randomization .  
4. Follow -up will occur a t 1, 4, 12 and  24 weeks and 
consist of vision testing (including visual acuity  and 
visual function ( myVisionTrack ), ocular exam, and 
OCT .  
5. Rescue vitrectomy may be performed if there is a 10 
or more letter  decrease at one visit or 5 or more 
letter decrease at two consecutive  visits compared 
JAEB CENTER FOR HEALTH RESEARCH  
Gas for VMT v3.0 7 -24-19           
    PARTICIPANT AREA  DESCRIPTION  
with baseline that is thought to be associated with 
VMT, or a complication that requires prompt 
surgical intervention (e.g. macular hole , retinal 
detachment, non -clearing vitreous hemorrhage ). 
Otherwise, alternative treatment may not be 
performed without discussion with and approval 
from the protocol chair or designee .  
6. The primary outcome assessment will be the 
proportion  of eyes with  central  VMT r elease  on 
OCT at 24 weeks  without rescue treatment . 
JAEB CENTER FOR HEALTH RESEARCH  
Gas for VMT v3.0 7 -24-19           
    SCHEMATIC OF STUDY DESIGN  
 Dropped IneligibleInformed Consent Obtained
Baseline Testing
Randomization
Injection of C3F8
Gas (0.3 mL)
1 week
4 week
12 week
24 week
Primary OutcomeObservation 
(Sham injection)
1 week
4 week
12 week
24 week
Primary OutcomeReading Center Review
Dropped 
Ineligible
Follow -Up Treatment  
Vitrectomy permitted in both arms if 
one of the following:  
1) Visual acuity  decreases ≥10 
letters  at one visit or ≥5 
letters at two consecutive 
visits  
2) Complication requires 
prompt surgical 
intervention (e.g. , macular 
hole)  Follow -Up Treatment  
Vitrectomy permitted in both arms if 
one of the following:  
1) Visual acuity  decreases ≥10 
letters  at one visit or ≥5 
letters at 2 consecutive 
visits (not including the 1 -
week visit) compared with 
baseline that is thought to 
be related to VMT.  
2) Complication requires 
prompt surgical 
intervention (e.g. , macular 
hole, retinal detachment, 
non-clearing vitreous 
hemorrhage ). 
 
JAEB CENTER FOR HEALTH RESEARCH  
Gas for VMT v3.0 7 -24-19           
    SCHEDULE OF STUDY VISITS AND PROCEDURES  
 
 Baseline Testing 
and 
Randomization*  1 and 4 weeks   
12 and 24 
weeks  
E-ETDRS best corrected visual acuity a X X X 
Visual function testing  
(myVisionTrack) b X  X 
OCT c X X X 
Eye exam d X X X 
Reading center eligibility confirmation e X   
Randomized treatment (gas or sham 
injection) X   
* All baseline testing must occur within 8 days prior to randomization . Baseline testing  and randomization can occur 
on the same day if eligibility is confirmed by reading center on day of screening .  
 
a, Both eyes at all visits; includes protocol refraction in study eye only at 1, 4, and 12 weeks and in both eyes at baseline and 24 
week s; E-ETDRS refers to electronic ETDRS testing using the Electronic Visual Acuity Tester that has been validated against 4 -
meter chart ETDRS testing.  
b, At baseline , 12, and 24 weeks . 
c, Both eyes at baseline; study eye only at follow up visits.  
d, Both eyes at  baseline; study eye only at each follow -up visit . Includes slit lamp exam (including assessment of lens), 
measurement of IOP, and dilated ophthalmoscopy.  Scleral depression is required at baseline to confirm eligibility. During follow 
up, the eye exam should be extensive enough to identify adverse event s of interest . An extended ophthalmoscopy including a  
scleral depression is required at 1, 4, and 12 weeks.  
e, Reading center review of  the OCT for  eligibility must occur prior to randomization .
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         1-1  
   CHAPTER 1:  BACKGROUND INFORMATION AND STUDY SYNOPSIS  1 
 2 
1.1. Introduction  3 
1.1.1 Vitreoretinal Interface Abnormalities  4 
Disorders of the vitreoretinal interface represent a spectrum of abnormalities that develop as the 5 
posterior hyaloid separates from the internal limiting membrane . Vitreomacular adhesion (VMA) 6 
occurs when the posterior hyaloid remains attached to the internal limiting membrane centrally . 7 
Overall, about 1.5% of the population is estimated to have eye diseases caused by or associated 8 
with VMA.1 The incidence of VMA diagnoses is expected to increase with widespread use of 9 
spectral -domain optical coherence tomography ( OCT ). Vitreomacular traction (VMT) is 10 
diagnosed when VMA results in traction, distortion of retinal architecture, and patient 11 
symptomatology.2 The prevalence of VMT has been reported to be 22.5 per 100,000 of the 12 
population, with an annu al incidence of 0.6 per 100,0002. However, these rates , determined 13 
before widespread use of spectral -domain OCT , are likely an underestimation . Advanced VMT 14 
can lead to macular holes (MH), in which tractional forces create small , full-thickness defects on 15 
the posterior fundus, often requiring surgical intervention.2  16 
1.1.2 Treatment s for VMT  17 
Treatment options for VMT in clude observation, vitrectomy, and intraocular injection of 18 
ocrip lasmin . Observation may not be an optimal choice in symptomatic patients . There have 19 
been multiple reports in the literature of spontaneous resolution of VMT. 3-8 Based on a 20 
Cochrane Eyes and Vision systematic review of 4 trials with 932 eyes, the 28 -day VMA release 21 
rate among eyes in the control groups (sham or saline injection) is estimated to be 97  of 1000 22 
eyes.9 In the Intravitreal Inj ection -Traction Release Without Surgical T reatment (MIVI -TRUST) 23 
trials,10 10% of the placebo -vehicle injected eyes developed a spontaneous posterior vitreous 24 
detachment ( PVD ) by 28 days, increasing to about 13% through 180 days . The Ocriplasmin for 25 
Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Trial 26 
reported success of VMT release of 6% in the sham group at 28 days, increasing to 14% over 2 27 
years.11 In a 2014  retrospective case series , John et al6 reported spontaneous PVD in 32% of eyes 28 
with focal VMA (document ed by spectral -domain OCT) and good vision ( mean  visual acuity: 29 
20/37) with a median follow -up time of 18 months . Thus, observation alone may yield a 30 
spontaneous resolution of visual impairment after a waiting period of sufficient time, although 31 
the precise timing of the spontaneous resolution is unpred ictable and can be prolonged.  32 
Vitrectomy  is a viable alternative to observation. However, vitrectomy  is costly and carries a risk 33 
of complications such as endophthalmitis, retinal detachment and cataract progression, even 34 
when performed by experienced sur geons.  Therefore, v itrectomy is generally reserved for eyes 35 
with more advanced VMT as sociated with relatively poor visual acuity  level.  36 
In 2012, the MIVI -TRUST trial showed that ocriplasmin  (Jetrea®), a proteolytic enzyme for 37 
treatment of symptomatic VMA , induced a PVD in 26.5% of eyes versus 10.1% of placebo - 38 
vehicle injected eyes.10, 12 The success was shown to increase to 40% in eyes without epiretinal 39 
membrane.10 In 2016, Lim et al reported in the Macula Society Collaborative Retrospective 40 
Study a rate of 45% in release of VMT after ocriplasmin.13 Based on the Cochrane Eyes and 41 
Vision systematic review, the 28 -day release rate among eyes treated with ocriplasmin is 42 
estimated to be 237  of 1000  eyes.9 However, there have been multiple anecdotal reports of 43 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         1-2  
   substantial ocular complications associated with intraocular administration of ocriplasmin,14-18 44 
including transient visual loss, persistent dyschromatopsia, electroretinograp hic abnormalities, 45 
subluxation of the crystalline lens likely related to zonulolysis, and disturbance or dehiscence of 46 
the ellipsoid layer documented by OCT. These adverse events have created major concerns 47 
among many retinal surgeons in the clinical use o f this drug.14-18 In a recent American Socie ty of 48 
Retina Specialists Preferences and Trends Survey, only 7% of retina specialists recommended 49 
ocriplasmin as first line therapy for VMT and visual acuity of 20/60  or worse .19 50 
1.1.3 Pneumatic Vitreolysis  (PVL)  51 
Pneumatic vitreolysis (intraocular injection of expansile gas to induce a PVD) has b een 52 
suggested as a potential treatment alternative to ocriplasmin for resolving VM T without surgery . 53 
Chan et al first demonstrated and reported the utility of intraocular gas (C 3F8) injection in 54 
eliciting a PVD (9 5%) in 1995.20 Subsequently, Costa et al, and Jorge et al showed a high rate of 55 
success in the induction of PVD (100%) with C 3F8 in small case series.21, 22 Recently, Rodrigues 56 
et al, in a series of fifteen eyes, showed resolution of VMT in 40% at one month and 60%  by 6 57 
months after injection of C 3F8 gas.23 Steinle et al reported a success rate of 83% with C 3F8 gas in 58 
a retrospective case series for treatment of VMT syndrome.24 In a 2016  retrospective review of 59 
50 consecutive eyes receiving C 3F8 gas for PVL  performed in 2 centers , Chan and Mein reported  60 
a success rate of 86% in VMT release (80% success for VMT -only eyes and 100% for small 61 
stage  2 MH [≤ 250 microns]).25 In 2019, Chan and Mein provided an update on this study and 62 
reported a success rate of 85% among 80 e yes (80.7% in eyes with VMT -only, 95.7% in eyes 63 
with macular hole) .26 However, all of these cited case series involving PVL  involved relatively 64 
small numbers of cases and did not incorporate control arms for comparison .  65 
1.2. Rationale  66 
Given the low cost and convenience of gas injection in the office setting as well as a low rate of 67 
adverse events reported in prior retrospective studies, PVL  may serve as an alternative to either 68 
potentially less effective observation or much more costly treatments with well -established 69 
associated adverse events such as ocriplasmin or vitrectomy for managing VMT. Although many 70 
eyes with VMT have good vision  and are not symptomatic, there are also many patients who 71 
experience central visual loss or symptoms such as metamorphopsia  due to persistent VMT . 72 
Therefore, a randomized clinical trial is indicated to evaluate the safety and efficacy of 73 
intraocular gas injection for treatment of VMT without a MH in patients who are symptomatic 74 
and desire intervention .  75 
The purpose of this stu dy is not to compare release rates directly with vitrectomy . Instead, the 76 
goal is to evaluate PVL compared with observation to determine if it is a  viable first -line 77 
treatment option  to consider before resorting to vitrectomy . If PVL is successful for managing  78 
VMT, its use may reduce the need for current therapies by both resolving VMT and preventing 79 
MH formation in early cases and by closing small stage -2 MH in the advanced cases .  80 
1.3 Study Objective s 81 
Primary  82 
1. To compare the proportion of eyes with central  VMT  release on OCT from  PVL  with gas 83 
injection versus observation (sham  injection ) in eyes with VMT  without an associated 84 
MH.  85 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         1-3  
   Secondary  86 
2. To evaluate visual function outcomes at 24 weeks after gas injection is performed 87 
compared with observation.  88 
1.4 Potential Risks and Benefits of C3F8 Gas Injection  89 
1.4.1 Known Potential Risks  90 
• Pain, discomfort, redness, or itching lasting for a few days is likely.  91 
• Subconjunctival hemorrhage or floaters will commonly occur as a result of the injection . The 92 
floaters are typically reduced after 6  to 8 weeks, but some floaters may persist.  93 
• Immediately following the injection, there may be elevation of IOP. It usually returns to 94 
normal spontaneously, but may need to be treated with topical dru gs or a paracentesis to 95 
lower the pressure . The likelihood of permanent loss of vision from elevated IOP is less than 96 
1%. 97 
• Although it has not been reported in prior case series, endophthalmitis could theoretically 98 
develop . The risk of endophthalmitis from other intraocular injections is less than 1%.  99 
• A retinal tear or detachment could occur . The risk of retinal breaks and/or detachment after 100 
gas injection is approximately  5-13%. The risk of retinal detachment is increased if there are 101 
pre-existing periphera l retinal abnormalities such as lattice degeneration or cystic tufts.  102 
• There is a possibility of traumatic cataract from the injection. The risk of developing a 103 
cataract from the injection is <1%.   104 
• If paracentesis is performed, there is a similar risk  of traumatic cataract from the 105 
paracentesis.  106 
• If vitrectomy is required while gas is in the eye, there is high likelihood of cataract formation 107 
during surgery that may require cataract removal at the time of vitrectomy.  108 
• Progression to MH after gas injection is a potential complication. Previous retrospective 109 
studies have shown this complication to be <5%  110 
• Limited and transient uveitis may develop after gas injection . Persistent uveitis is uncommon.  111 
• Limited transient conjunctival or episcleral hemorrhage is common shortly after gas 112 
injection.  It is usually inconsequential and clears spontaneously from a few days to a week or 113 
two.  114 
• Limited vitreous hemorrhage after gas injection is uncommon but may occur occasionally 115 
after gas injection, particularly given a history of active anticoagulation therapy or 116 
predisposing risk for hemorrhage . If present, it usually resolves from a few days to a few 117 
months . Marked hemorrhage requiring a surgical intervention after gas injection is 118 
exceedingly rare  (<1%).  119 
• Pre-existing epiretinal fibrosis may sometimes progress or new epiretinal fibrosis may 120 
develop after gas injection.  121 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         1-4  
   • The development of excessive scarring on top of or under the retina after gas injection is 122 
exceedingly rare. When this occurs, it i s usually associated with advanced retinal 123 
detachment, which is also uncommon after gas injection.  124 
Additional risks if the participant does not follow post -injection instructions:  125 
• IOP may increase if the patient experiences changes in elevation (i.e. trave l by air or over 126 
mountain ranges)  while the gas bubble is still present in the eye . 127 
• Loss of vision or blindness  is possible  if nitrous oxide anesthesia is administered with the gas 128 
bubble still present in the eye . 129 
• Incorrect head positioning following the g as injection may lead to glaucoma or cataracts . 130 
1.4.2 Known Potential Benefits  131 
Potential benefits from participation in the study for eyes randomly assigned to PVL include 132 
release of VMT, improved visual acuity , improved quality of vision, prevention of fu ll-thickness 133 
macular hole, and avoidance of more invasive and expensive procedure s, i.e., vitrectomy, 134 
ocriplasmin.  135 
1.4.3 Risk Assessment  136 
The risk level is considered to be research involving greater than minimal risk.  137 
1.5 General Considerations  138 
The study is be ing conducted in compliance with the policies described in the study policies 139 
document, with the ethical principles that have their origin in the Declaration of Helsinki, with 140 
the protocol described herein, and with the standards of Good Clinical Practice (GCP).  141 
The DRCR Retina Network  procedures manuals provide details of the procedures .  142 
VA and OCT technicians will be masked to treatment group at all visits . The goal is for s tudy 143 
participants to remain  masked to their treatment group assignment , although it is likely  that the 144 
gas bubble will be visible to participants in the PVL group . Investigators and study coordinators 145 
are not masked to treatment group.  146 
Data will be directly collected in electronic c ase report forms, which will be considered the 147 
source data.  148 
There is no restriction on the number of subjects to be enrolled by each site towards the overall 149 
recruitment goal.  However, recruitment will be monitored on an ongoing basis and the sponsor 150 
can d ecide to place recruitment at a particular site on hold as needed.  151 
All consented participants will be logged.  152 
The protocol is considered a significant risk device study because intraocular injection of C 3F8 is 153 
experimental for this indication . Therefore, an investigational device exemption (IDE) from the 154 
U.S. Food and Drug Administration (FDA) is required to conduct the study. 155 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         2-1  
   CHAPTER 2:  STUDY PARTICIPANT ELIGIBILITY AND ENROLLMENT  156 
2.1 Randomized Trial Participant Recruitment and Enrollment  157 
Enrollment will proceed with the goal of at least 124 participants being randomized . Participants 158 
who have signed consent  may be permitted to continue into the trial, if eligible, even if the 159 
randomization goal has been reached.  160 
Study partic ipants will be recruited from approximately 50 clinical centers in the United States . 161 
Approximately 10 participants are expected to be randomized each month, resulting in 13 162 
months of recruitment, for a total study duration of 19 months.  163 
All eligible participants will be included without regard to gender, race, or ethnicity . There is no 164 
restriction on the number of participants to be enrolled by each site toward the overall 165 
recruitment goal.  166 
Potential eligibility may be assessed as part of a routine -care examination . Before completing 167 
any procedures or collecting any data that are not part of usual care, wr itten informed consent 168 
will be obtained.  169 
The study protocol will be discussed with the potential study participant by study staff . The 170 
potential study participant will be given the Informed Consent Form to read . Potential study 171 
participants will be encoura ged to discuss the study with family members and their personal 172 
physicians(s) before deciding whether to participate in the study.  173 
As part of the informed consent process, each participant will be asked to sign an authorization 174 
for release of personal info rmation . The investigator, or his or her designee, will review the 175 
study -specific information that will be collected and to whom that information will be disclosed . 176 
After speaking with the participant, questions will be answered about the details regarding  177 
authorization.  178 
Once a study participant is randomized, that participant will be counted regardless of whether the 179 
assigned treatment is received . Thus, the investigator must not proceed to randomize an 180 
individual until he/she is convinced that the individ ual is eligible and will accept assignment to 181 
either of the two treatment groups .  182 
2.2 Participant Eligibility Criteria  183 
2.2.1 Participant -level Criteria  184 
Inclusion  185 
To be eligible, the following inclusion criteria must be met:  186 
1. Age ≥18 years .  187 
• Participants <18 years old are not being included because the condition  is so rare in this 188 
age group that the diagnosis may be questionable.   189 
2. At least one eye meets the study eye criteria listed in section 2.2.2.  190 
3. Able and willing to provide informed consent.  191 
4. Able and willing to avoid high altitude travel , including airline travel , until gas resolution 192 
(approximately 6 to 8 weeks ).  193 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         2-2  
   5. For phakic patients, a ble and willing to avoid supine position until gas resolution  194 
(approximately 6 to 8 weeks ). 195 
6. Able and willing  to wear wrist band that informs any medical personnel that the patient has a 196 
gas bubble in the eye  197 
Exclusion  198 
A potential participant is not eligible if any of the following exclusion criteria are present:  199 
7. A condition that, in the opinio n of the investigator, would preclude participation in the study 200 
(e.g., unstable medical status  that might preclude completion of follow -up) 201 
8. Participation in an investigational trial within 30 days of randomization that involves 202 
treatment with any drug or device that has not received regulatory approval for the indication 203 
being studied at the time of study entry  204 
• Note: study participants should not  receive another investigational drug /device  while 205 
participating in the study  206 
9. Known contraindication  to any component of the treatment  207 
10. Known allergy to any drug used in the procedure  prep (including povidone iodine)  208 
11. Potential participant is expecting to move out of the area of the clinical center to an area not 209 
covered by another cl inical center during the next 6 months  following randomization  210 
12. Anticipated surgery requiring anesthesia within the next 6 months following randomization  211 
• Participants cannot receive nitrous oxide until gas resolution  212 
13. For women of child -bearing potential , pregnant at the time of enrollment  213 
• Women who are potential study participants should be questioned about the potential for 214 
pregnancy. Investigator judgement may be used to determine when a pregnancy test is 215 
needed.  216 
2.2.2 Study Eye Criteria  217 
The participant must have at least one eye meeting all of the inclusion criteria and none of the 218 
exclusion criteria listed below.  219 
A participant can have only one study eye . If both eyes are eligible at the time of randomization, 220 
the study eye will be selected by the investigator and participant before randomization .  221 
The eligibility criteria for a study eye are as follows:  222 
Inclusion  223 
a. Central v itreomacular adhesion on OCT that is no larger than 3000 microns  with visible 224 
separation of the vitreous on either side a s seen on horizontal and vertical scans , confirmed 225 
by central reading center  226 
Note: p resence of epiretinal membrane is neither a requirement nor exclusion.  227 
b. Decreased visual function (e.g. metamorphopsia or other visual symptom) that is attributed to 228 
VMT.   229 
Examples of  visual  symptoms include:  230 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         2-3  
   a) Distortion and/or reduction in visual acuity  231 
b) Recognized difficulty with reading, driving, or using a computer  232 
c) Patient recognized interference with quality of life because of a and/or b.  233 
 234 
c. Visual acuity letter score of at least 19 (appr oximate Snellen equivalent 20/400  or better ) and 235 
at most 78 (20/32 or worse)  236 
d. Investigator and participant willing to wait 6 months before surgical intervention , provided  237 
visual acuity remains stable   238 
• An eye that requires  prompt treatment for VMT should not be enrolled  239 
Exclusion  240 
e. Other ocular condition that might affect visual acuity during the course of the study  or 241 
require intraocular treatment  (e.g., retinal vein occlusion , substantial age-related macular 242 
degeneration , or macular edema induced by a condition other than VMT)  243 
• If diabetic retinopathy is present, severity level must be microaneurysms only or better (≤  244 
diabetic retinopathy  severity level 20)  245 
• Presence of drusen is acceptable; however, eyes with geograph ic atrophy  or neovascular 246 
age-related macular degeneration involving the macula are excluded  247 
f. High level of myopia ( spherical equivalent of -8.00 diopters or more  myopic if phakic or 248 
retinal abnormalities consistent with pathologic myopia if phakic or pseudo phakic ) 249 
g. History of prior gas injection, ocriplasmin injection, or intraocular injection for any reason  250 
h. History of prior vitrectomy  251 
i. History of uncontrolled glaucoma  252 
• IOP must be <30  mmHg , with no more than one topical glaucoma medication, and no 253 
documented g laucomatous field loss for the eye to be eligible  254 
j. History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular 255 
surgery, etc.) within prior 4 months or major ocular surgery anticipated within the next 6 256 
months following ra ndomization  257 
k. History of YAG capsulotomy performed within 4 months prior to randomization  258 
l. Aphakia  or anterior c hamber intraocular lens  259 
m. Exam evidence of severe external ocular infection, including conjunctivitis, chalazion, or 260 
substantial blepharitis  261 
n. Uveitis  262 
o. Presence of any macular hole or lamellar hole (according to reading center grading)  263 
p. Retinal history or pathology that might predispose an eye to an increased risk of retinal 264 
detachment from the procedure  265 
• Untreated retinal tears , not re tinal holes, are an exclusion.  It is up to the investigator to 266 
determine whether extent of lattice degeneration or other pathology might increase the 267 
risk of retinal detachment.  268 
q. Any contraindication to paracentesis (e.g ., history of narrow angle glaucoma)  269 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         2-4  
   r. Lenticular or zonular instability  270 
2.3 Screening Evaluation and Baseline Testing  271 
After informed consent has been signed, a potential participant will be evaluated for study 272 
eligibility through the e licitation of a medical history and  performance of an ocular  examination 273 
by study personnel to screen for exclusionary conditions.  274 
Individuals who do not initially meet study eligibility requirements may be rescreened at a later 275 
date per investigator discretion.  276 
All testing does not need to be completed on the same da y provided it is within the windows 277 
specified below . Reading Center confirmation of VMT on OCT must be completed prior to 278 
randomization .  279 
2.3.1 Baseline Testing  Procedures  280 
The following procedures are needed to confirm eligibility and/or to serve as baseline measures 281 
for the study:   282 
• If a procedure has been performed using the study technique and by study certified 283 
personnel as part of usual care, then it does not need to be repeated specifically for the 284 
study if it was performed within the defined tim e windows specified below.  285 
• The testing procedures are detailed in the DRCR Retina Network  Procedures Manuals . 286 
Visual acuity testing, ocular exam, visual function testing, and OCT will be performed by 287 
DRCR Retina Network  certified personnel.  288 
1. Self-reported d emographics (date of birth, sex, race and ethnicity)  289 
2. Medical history (pre -existing medical conditions, concomitant medications, as well as ocular 290 
diseases, surgeries, and treatments ) 291 
➢ Medical history will be obtained by medical charts if avai lable at the enrolling site; 292 
otherwise, it will be self -reported  293 
3. Electronic -ETDRS visual acuity testing at 3 meters using the Electronic Visual Acuity Tester 294 
(including protocol refraction) in each eye  (within prior 8 days)  295 
4. Visual function testing ( myVisio nTrack ) (within prior 8 days)  296 
➢ Visual function testing will be performed using the myVisionTrack application on an 297 
iPad or tablet. myVisionTrack ® is an FDA cleared application to track disease 298 
progression in patients with certain retinal diseases.  During the test, the patient will 299 
select the circle that is shaped differently among a series of  side-by-side circles on the 300 
screen . The series  continues  with increasing difficulty  until the patient’s visual 301 
function is determined. Visual function is measu red using the shape discrimination 302 
hyperacuity (SDH) (logMAR) score.   303 
5. Spectral -Domain OCT using Zeiss Cirrus or Heidelberg Spectralis on each eye  (within prior 304 
8 days)  305 
➢ OCT  scans of the study eye will be promptly sent to the central reading center for 306 
gradi ng and a participant cannot be randomized until reading center confirmation of 307 
eligibility has been received  308 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         2-5  
   6. Ocular examination on each eye including slit lamp, measurement of IOP, lens assessment, 309 
and dilated ophthalmoscopy (within prior 8 days ) 310 
➢ Scleral depression to rule out any retinal tears pre -operatively will be required for the 311 
baseline eye exam to confirm eligibility  312 
2.4 Randomization of Eligible Participants  313 
Randomization may occur on the same day as baseline testing if eligibility is confirme d by the 314 
reading center on the day of screening .  315 
1. Prior to randomization, the participant’s understanding of the trial, willingness to accept the 316 
assigned treatment group, and commitment to the follow -up schedule should be reconfirmed.  317 
2. The baseline injection (or sham) must be given on the day of randomization; therefore, a 318 
participant should not be randomized until this is possible .  319 
3. Randomization is completed on the DRCR Retina Network  website .  320 
• Study eyes will be randomly assigned with equal probab ility to one of two treatment 321 
groups:  322 
o Group A: PVL ( Intravitreous injection of  0.3 mL  C3F8 gas) 323 
o Group B: Observation ( Sham injection ) 324 
Randomization will be stratified by clinical site and presence of epiretinal membrane (ERM) 325 
within 1 mm of the center of the macula , determined by Reading Center grading . Previous 326 
reports have suggested  that the proportions  of eyes with VMT release  differ depending on the 327 
presence of ERM.   328 
Once a study participant is randomized, that participant will be counted regardless of whether the  329 
assigned treatment is received . Thus, the investigator must not proceed to randomize an 330 
individual until he/she is convinced that the individual is eligible and will accept whichever 331 
treatment group is assigned through randomizati on. 332 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         3-1  
   CHAPTER 3:  BASELINE TREATMENT  333 
3.1 Treatment  334 
For both groups, the baseline injection (sham or intravitreous) must be given on the day of 335 
randomization .  336 
3.2 Injection  Procedure  337 
3.2.1 Intravitreous Injection Technique  338 
The injection is preceded by a povid one iodine prep of the conjunctiva . A subconjunctival 339 
injection of lidocaine may be administered , at the discretion of the investigator . The injection 340 
will be performed using sterile technique . Pre-injection paracentesis should be considered due to 341 
the 4x expansion of C 3F8 gas and the associated risk of shallowing of the anterior chamber . 342 
However, the choice of when or whether or not to do a paracentesis is ultimately at the 343 
investigator’s discretion. The full injection procedure is described in the protocol -specific study 344 
procedures manual . Topical antibiotics in the pre -, peri -, or post -injection period should not be 345 
used without prior approval from the Protocol Chair or Coordinating Center designee.  346 
 347 
3.2.2 Aqueous Sample Collection  348 
Participation in the ancillary sample collection component is not a requirement for participation 349 
in this study . It is expected that sites with the capability to ship intraocular fluids will participate . 350 
At the time of consent into the main study, participants will have the option of signing the 351 
ancillary sample collection portion of the informed consent form to indicate their willingness to 352 
provide the sample for future use . If paracentesis is performed and participant consent is 353 
obtained, aqueous fluid  already being drawn as part of paracentesis may be collected and shipped 354 
on dry ice to a central lab oratory  for storage  for future analyses . Sites will be encouraged to 355 
collect aqueous samples when performing paracentesis, though sample collection will not be 356 
required . Details regarding collection, sample labeling, storage, and shipment can be found in the 357 
procedures manual.   358 
3.2.3 Sham Injection Technique  359 
The prep will be performed as for an intravitreous injection . For the sham injection procedure, a  360 
syringe without a needle will be used, with the hub pressed against the injection site  to simulate 361 
the force of a n actual injection.  362 
3.3 Participant Instructions Post -Injection  363 
Participants will be given a post -injection instruction sheet informing them of all post -injection  364 
requirements and risks if they do not follow  these requirement s. All partic ipants will be 365 
instructed to avoid high altitude travel until the surgeon confirms the gas bubble has cleared.  366 
Phakic p articipants in both groups will be asked to avoid the supine position and lie on one side 367 
or the stomach during sleeping hours until the surgeon confirms that the gas bubble has cleared . 368 
All participants will be instructed to wear a wristband to notify healthcare providers that they 369 
should not receive nitrous oxide anesthesia until the gas bubble has cleared. For observation 370 
group participa nts, this will be the 4 -week visit.  371 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         4-1  
   CHAPTER 4:  FOLLOW -UP VISITS AND TESTING  372 
4.1 Study Visit s 373 
The schedule of protocol -specified follow -up visits is as follows:  374 
• 1 week ( - 4 days to + 3  days)  375 
• 4 (±1) weeks  376 
• 12 (± 2) weeks  377 
• 24 (±4) weeks  378 
4.1.1 Procedures at Study Visits  379 
The following procedures will be performed in both groups at all visits, unless otherwise 380 
specified : 381 
1. E-ETDRS visual acuity testing (best corrected) in each eye.  382 
• A protocol refraction in the study eye is required at  each visit . Refraction in the non-study 383 
eye is only required at  the 24-week  visit. When a refraction is not performed, the most 384 
recently performed refraction is used for the testing.  385 
• VA technicians will be masked to treatment group at all visits . 386 
2. Visual function testing ( myVisionTrack ) at 12 and  24 weeks only   387 
3. Spectral -Domain OCT using Zeiss Cirrus or Heidelberg Spectralis on the study eye  388 
• The same machine type (Cirrus or Spectralis) used at baseline must be used during 389 
follow -up 390 
• OCT technicians will be masked to treatmen t group at all visits.  391 
4. Ocular exam  in the study eye only , including slit lamp examination with lens assessment, 392 
measurement of IOP, and dilated ophthalmoscopy  393 
• The eye exam should be extensive enough to identify adverse events of interest  394 
• An extended ophthalmoscopy including a  scleral depression is required at 1, 4, and 12 395 
weeks to identify any retinal tears or detachments  396 
All of the testing procedures do not need to be performed on the same day, provided that they are 397 
completed within the tim e window of a visit . If data from a testing procedure is unusable ( e.g., if 398 
OCT is ungradable), the participant may be asked to repeat the procedure during an additional 399 
visit, whether part of usual care or solely to repeat the procedure . 400 
4.1.2 Unscheduled Visit s 401 
Additional visits may occur as required for usual care of the study participant.   402 
Testing procedures at unscheduled visits are at investigator discretion . However, it is 403 
recommended that procedures that are performed should follow the standard DRCR Retin a 404 
Network  protocol for each procedure . 405 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         4-2  
   4.2 Treatment During Follow -Up 406 
4.2.1 Criteria for Vitrectomy  407 
Vitrectomy may be performed if one of the following  occurs : 408 
1. Visual acuity  decreases at least 10 letters at a single visit (not including the 1 -week visit) or 409 
at least 5 letters at two consecutive visits (not including t he 1-week visit) compared with 410 
baseline that is thought to be related to VMT  411 
2. Complication requires prompt surgical intervention (e.g. , macular hole , retinal de tachment, 412 
non-clearing vitreous hemorrhage ) 413 
Otherwise, protocol chair approval must be obtained for alternative treatment.  414 
4.2.2 Treatment for Other Conditions in the Study Eye  415 
An eye should not be enrolled that is anticipated to require intraocular treatment for another 416 
condition during the study. If a condition develops during follow -up requiring prompt treatment, 417 
it is at investigator discretion .  418 
4.2.3 Treatment in the Non -Study Eye  419 
Treatment in the non -study eye is at investigator discretion , except that gas injec tion for VMT is 420 
not permitted in the non -study eye during the study .  421 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         5-1  
   CHAPTER 5:  STUDY DEVICE  422 
5.1 Description of the Investigational Device  423 
Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the 424 
vitreous cavity.  It was approved by the FDA in February 1993 (P900066) for the use of placing 425 
pressure on detached retina.  426 
5.2 Study Device Accountability Procedures  427 
Each participating site will use their own commercially available perfluoropropane  C3F8. It must 428 
be stored at room temperature . Prior to each injection, the investigator must confirm that the 429 
cylinder pressure is at least 50 psi  and the cylinder is not expired .  430 
5.3 Safety Measures  431 
Preparation of the p erfluoropropane C 3F8 injection will be performed  in accordance with 432 
manufacturer labelling.  The full injection procedure is described in the protocol -specific study 433 
procedures manual. 434 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         6-1  
   CHAPTER 6:  ADVERSE EVENTS, DEVIC E ISSUES, AND STOPPING RULES  435 
6.1 Adverse Events  436 
6.1.1 Definitions  437 
Adverse Event (AE):  Any untoward medical occurrence in a study participant, irrespective of the 438 
relationship between the adverse event and the device(s) under investigation (see section 6. 2 for 439 
reportable adverse events for this protocol) . 440 
Serious Adverse Event (SAE):  Any untoward medical occurrence that:  441 
• Results in death.  442 
• Is life -threatening; (a non -life-threatening event which, had it been more severe, might 443 
have become life -threatening, is not nec essarily considered a serious adverse event).  444 
• Requires inpatient hospitalization or prolongation of existing hospitalization.  445 
• Results in persistent or significant disability/incapacity or substantial disruption of the 446 
ability to conduct normal life functio ns (e.g. sight threatening).  447 
• Is a congenital anomaly or birth defect.  448 
• Is considered a significant medical event by the investigator based on medical judgment 449 
(e.g., may jeopardize the participant or may require medical/surgical intervention to 450 
prevent one of the outcomes listed above).  451 
In general, an ocular adverse event should be reported as serious (considered sight threatening) if 452 
it meets one of the following criteria:  453 
1. It causes a decrease of ≥ 30 letters in visual acuity compared with the last visua l acuity 454 
measurement prior to onset (e.g. central retinal artery occlusion) . 455 
2. In the opinion of the investigator, it requires prompt surgical intervention (e.g. 456 
vitrectomy, vitreous tap, intravitreous antibiotics , laser or cryosurgical retinopexy ) to 457 
prevent permanent loss of sight.  Examples include endophthalmitis , retinal tear,  or 458 
rhegmatogenous retinal detachment.  459 
Ocular adverse events that do not have the potential to result in permanent loss of sight would 460 
not be considered serious.  461 
Unanticipated Adverse Device Effect (UADE):  Any serious adverse effect on health or safety or 462 
any life -threatening problem or death caused by, or associated with, a device, if that effect, 463 
problem, or death was not previously identified in nature, severity , or degree of incidence in the 464 
investigational plan or application (including a supplementary plan or application), or any other 465 
unanticipated serious problem associated with a device that relates to the rights, safety, or 466 
welfare of participants (21 CFR 812.3(s)).  467 
Adverse Device Effect (ADE):  Any untoward medical occurrence in a study participant which 468 
the device may have caused or to which the device may have contributed (Note that an Adverse 469 
Event Form is to be completed in addition to being reported on a Gas Injection Form ). 470 
Device Complaints:  A device complication or complaint is something that happens to a device or 471 
related to device performance, whereas an adverse event happens to a participant . A device 472 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         6-2  
   complaint may occur independently f rom an AE, or along with an AE . An AE may occur without 473 
a device complaint or there may be an AE related to a device complaint.  474 
Device Malfunction:  Any failure of a device to meet its performance specifications or otherwise 475 
perform as intended . Performance  specifications include all claims made in the labeling for the 476 
device . The intended performance of a device refers to the intended use for which the device is 477 
labeled or marketed. (21 CFR 803.3)  478 
6.1.2 Reportable Adverse Events  479 
For this protocol, a reportable ad verse event includes any untoward medical occurrence that 480 
meets one of the following criteria:  481 
1) an ocular AE in the study eye , 482 
2) a serious AE, 483 
3) an Adverse Device Effect (ADE) as defined in section 6.1.1 , or 484 
4) an AE occurring in association with a study procedure .  485 
All reportable adverse events  whether they are volunteered by the participant, discovered by 486 
study personnel during questioning, or detected through physical examination, test ing procedure , 487 
or other means , will be reported on an Adverse Event Form onlin e. Each Adverse Event Form is 488 
reviewed by the Medical Monitor to verify the coding and the reporting that is required.  489 
6.1.3 Relationship of Adverse Event to Study Device  490 
The study investigator will assess the relationship of any adverse event to be related or u nrelated 491 
by determining if there is a reasonable possibility that the adverse event may have been caused 492 
by the study device.  493 
To ensure consistency of adverse event causality assessments, investigators should apply the 494 
following general guideline when dete rmining whether an adverse event is related:  495 
Yes 496 
There is a plausible temporal relationship between the onset of the adverse event and the study 497 
intervention, and the adverse event cannot be readily explained by the participant’s clinical state, 498 
intercurre nt illness, or concomitant therapies; and/or the adverse event follows a known pattern 499 
of response to the study intervention . 500 
No 501 
Evidence exists that the adverse event has an etiology other than the study intervention (e.g., pre - 502 
existing medical condition, underlying disease, intercurrent illness, or concomitant medication) , 503 
and/or the adverse event has no plausible temporal relationship to study intervention.  504 
6.1.4 Intensity of Adverse Event  505 
The intensity of an adverse event will be rated on a 3 point scale: (1) mild, (2) moderate, or (3) 506 
severe . It is emphasized that the term severe is a measure of intensity: thus a severe adverse 507 
event is not necessarily serious . For example, itching for several days may be rated as severe, but 508 
may not be clinically s erious.  509 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         6-3  
   • MILD: Usually transient, requires no special treatment, and does not interfere with the 510 
participant’s daily activities.  511 
• MODERATE: Usually causes a low level of inconvenience or concern to the participant 512 
and may interfere with daily activities, but  is usually ameliorated by simple therapeutic 513 
measures.  514 
• SEVERE: Interrupts a participant’s usual daily activities and generally requires systemic 515 
drug therapy or other treatment.  516 
6.1.5 Coding of Adverse Events  517 
Adverse events will be coded using the MedDRA dictionary . The Medical Monitor will review 518 
the investigator’s assessment of causality and may agree or disagree . Both the investigator’s and 519 
Medical Monitor’s assessments will be recorded . The Medical Monitor will have the final say in 520 
determining the cau sality.  521 
Adverse events that continue after the participant’s discontinuation or completion of the study 522 
will be followed until their medical outcome is determined or until no further change in the 523 
condition is expected.  524 
6.1.6 Outcome of Adverse Event  525 
The outcome  of each reportable adverse event will be classified by the investigator as follows:  526 
• COMPLETE RECOVERY/ RESOLVED : The participant recovered from the AE/SAE 527 
without sequelae . Record the AE/SAE stop date.  528 
• RECOVERED/ RESOLVED WITH SEQUELAE : The event persisted and had stabilized 529 
without change in the event anticipated . Record the AE/SAE stop date.  530 
• FATAL : A fatal outcome is defined as the SAE that resulted in death . Only the event that 531 
was the cause of death should be reported as fatal . Adverse events and serious  adverse 532 
events  that were ongoing at the time of death , that were not the cause of death, will be 533 
recorded as ‘resolved ’ at the time of death.  534 
• ONGOING : An ongoing AE/SAE is defined as the event was ongoing with an 535 
undetermined outcome.  536 
 An ongoing outcome for which further improvement or worsening is possible will 537 
require follow -up by the site in order to determine the final outcome of the AE/SAE.  538 
 An ongoing outcome that is medically stable (further change not expected) will be 539 
documented as such and will no t require additional follow -up.  540 
 The outcome of an ongoing event at the time of death that was not the cause of death, 541 
will be updated and recorded as ‘resolved ’ with the date of death recorded as the stop 542 
date.  543 
All adverse events occurring during the stud y and continuing at study termination should be 544 
followed by the participant’s physician and evaluated with additional tests (if necessary) until 545 
diagnosis of the underlying cause, or resolution . Follow -up information should be recorded on 546 
source documents.   547 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         6-4  
   If any reported serious, related, or unexpected adverse events or UADEs are present when a 548 
participant completes the study, or if a participant is withdrawn from the study due to a  serious, 549 
related, or unexpected adverse event  or UADE , the participant will be contacted for re -evaluation 550 
within 2 weeks . If the adverse event has not resolved, additional follow -up will be performed as 551 
appropriate . Every effort should be made by the Investigator or delegate to contact the 552 
participant until the a dverse event has resolved or stabilized.  553 
6.2 Reportable Device Issues  554 
All UADEs, ADEs, device complaints, and device malfunctions will be reported on the Gas 555 
Injection Form  irrespective of whether an adverse event occurred . 556 
6.3 Pregnancy Reporting  557 
If pregnancy occ urs, the participant will remain in follow -up for the duration of the study . The 558 
occurrence of pregnancy will be reported on an Adverse Event  Form.  559 
6.4 Timing of Event Reporting  560 
Serious adverse events and  unexpected device -related adverse events must be report ed to the 561 
Coordinating Center within 24 hours via completion of the online case report  form.  562 
The Coordinating Center will notify all participating investigators of any adverse event that is 563 
serious, related, and unexpected. Notification will be made within  10 days after the Coordinating 564 
Center becomes aware of the event.  565 
Each principal investigator is responsible for reporting serious study -related adverse events and 566 
abiding by any other reporting requirements specific to his/her Institutional Review Board or 567 
Ethics Committee.  568 
Upon receipt of a UADE report, the JCHR  will investigate the UADE and if indicated, report the 569 
results of the investigation to the sites’ IRBs, and the FDA within 10 working days of the JCHR  570 
becoming aware of the UADE per 21CFR 812.46( b) (2) . The Medical Monitor must determine if 571 
the UADE presents an unreasonable risk to participants . If so, the Medical Monitor must ensure 572 
that all investigations, or parts of investigations presenting that risk, are terminated as soon as 573 
possible but no  later than 5 working days after the Medical Monitor makes this determination 574 
and no later than 15 working days after first receipt notice of the UADE.  575 
Device malfunctions will be handled by the site and manufacturer .  576 
6.5 Stopping Criteria  577 
6.5.1 Criteria for Suspending or Stopping Overall Study  578 
The Data and Safety Monitoring Committee ( DSMC ) will be informed of all unanticipated 579 
adverse device events that occur during the study and will review compiled safety data at 580 
periodic intervals . The DSMC may request su spension of study activities or stoppage of the 581 
study if deemed necessary based on the totality of safety data available.  582 
The study may be discontinued by the Executive Committee (with approval of the DSMC ) prior 583 
to the preplanned completion of follow -up for all study participants.  584 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         6-5  
   6.6 Independent Safety Oversight  585 
A DSMC will approve the protocol, template informed consent form, and substantive 586 
amendments and provide independent monitoring of adverse events . Cumulative adverse event 587 
data are tabulated semi -annu ally for review by the DSMC . Following each DSMC data review, a 588 
summary will be provided to the IRB. A list of specific adverse events to be reported 589 
expeditiously to the DSMC will be compiled and included as part of the DSMC Monitoring Plan  590 
document .  591 
6.7 Risks  592 
The potential risks associated with use of the study device are described in section 1.4.1.  593 
Additional risks are minor and/or infrequent and include:   594 
Risks Related to Testing Procedures  595 
Many  of the testing procedures in this study are part of daily ophthalmologic practice in the United 596 
States and pose few if any known risks.  597 
• Dilating eye drops will be used as part of the exam . There is a small risk of inducing a narrow - 598 
angle glaucoma attack from the pupil dilation . However, all participants will hav e had prior 599 
pupil dilation usually on multiple occasions and therefore the risk is extremely small .  600 
Risks Related Specifically to the Pre -Injection Preparation  601 
• There are potential side effects to subconjunctival anesthetic, which are rare . They include, but 602 
are not limited to, the following: damage to the eyeball by the needle, damage to the optic 603 
nerve, double vision lasting 24 hours or more.  604 
• Complications associated with paracentesis are uncommon, but may include uveitis, flat 605 
anterior chamber, corneal wound leak, hyphema, anterior vitreous prolapse, and/or pupillary 606 
block glaucoma  and cataract . Under certain circumstances, such complications may lead to 607 
vision loss.  608 
Risks if Pregnant  609 
According to the C 3F8 package insert, there are no known teratogenic effects when injected into 610 
the eye; however, caution should be used in pregnant women . Therefore, patients will not be 611 
allowed to participate in this study if pregnant. Women who become pregnant during the st udy 612 
will be asked to stay in the study since there is no follow -up treatment with the investigational 613 
product.  614 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         7-1  
   CHAPTER 7:  MISCELLANEOUS CONSIDERATIONS  615 
7.1 Prohibited Medications, Treatments, and Procedures  616 
The participant will be instructed tha t nitrous oxide anesthesia must not be administered unless 617 
the investigator has confirmed that the gas bubble is no longer present.  Wristbands notifying 618 
healthcare providers of this will be given to participants following the intravitreous or sham 619 
injectio n, and must  be worn until the investigator confirms that the gas bubble has cleared (at 4 - 620 
week visit for observation group  participants).  621 
7.2 Participant  Withdrawal  622 
Participation in the study is voluntary and a participant may withdraw at any time . If a study 623 
participant is considering withdrawal from the study, the principal investigator should personally 624 
speak to the individual about the reasons and every effort should be made to accommodate him 625 
or her .  626 
The goal for the study is to have as few losses t o follow -up as possible . The Coordinating Center 627 
will assist in the tracking of study participants who cannot be contacted by the site . The 628 
Coordinating Center will be responsible for classifying a study participant as lost to follow -up. 629 
For participants w ho withdraw, their data will be used up until the time of withdrawal.  630 
7.3 Discontinuation of Study  631 
The study may be discontinued by the Executive Committee (with approval of the DSMC ) prior 632 
to the preplanned completion of follow -up for all study participants.  633 
7.4 Confidentiality  634 
For security and confidentiality purposes, participants will be assigned an identifier that will be 635 
used instead of their name . Protected health information gathered for this study will be shared with 636 
the coordinating center, the Jaeb Cente r for Health Research in Tampa, FL .  637 
The Coordinating Center will be provided with contact information for each study participant . 638 
Permission to obtain such information will be included in the Informed Consent Form . The contact 639 
information may be maintained in a secure database and will be maintained separately from the 640 
study data.  641 
Phone contact from the Coordinating Center will be made with each study participant in the first 642 
month after enrollment . Additional phone contacts from the Coordinating Center will be made if 643 
necessary to facilitate the scheduling of the study participant for follow -up visits . A participant - 644 
oriented newsletter and a study logo item may be sent once .  645 
Study participants will be provided with a summary of the study results in a newsletter format 646 
after completion of the study by all participants .  647 
7.5 Participant Compensation  648 
Participant  compensation will be specified in the informed consent form.  649 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         8-1  
   CHAPTER 8:  STATISTICAL CONSIDERATIONS  650 
8.1 Statistical and Analytical Plans  651 
The approach to sample size and statistical analyses are summarized below. A detailed statistical 652 
analysis plan will be written and finalized prior to the first review of data by treatment group. 653 
The analysis plan synopsis in this chapter contains the fra mework of the anticipated final 654 
analysis plan.  655 
8.2 Statistical Hypotheses  656 
A test of superiority will be used in evaluating the following hypotheses for the primary 657 
outcome:  658 
Null Hypothesis (H 0): There is no difference in the proportion of  eyes with  central VMT release 659 
without rescue treatment between the PVL and observation groups at 24 weeks.  660 
Alternative Hypothesis (H a): There is a difference in the proportion of eyes with  central VMT 661 
release  without rescue treatment  between the PVL and observation  groups at 24 weeks.  662 
Similar hypothesis tests will be conducted for all secondary, exploratory, and safety outcomes.  663 
8.3 Sample Size  664 
8.3.1 Outcome Projections:  665 
Observation Group (sham injection)  666 
In a consecutive case series of 106 eyes with a median follow -up time of 18 months,6 the 667 
proportion of eyes with  spontaneous VMT release was 32%. The proportion of eyes w ith VMT 668 
release at 6 months in the Sham Groups of the randomized controlled trials MIVI -TRUST10 669 
(N = 188) and OASIS (N = 74),11 which compared ocriplasmin versus sham for VMT, were 670 
approximately 13% and 10%, respectively. Dugel et al.11 also found that the proportion of eyes 671 
with VMT release was greater among eyes that had MH at baseline. Macular hole was present at 672 
baseline in approximately 36% of the OASIS Sham Group and 25% of the MIVI -TRUST Sham 673 
Group.  674 
PVL group  675 
Three case series provide  estimates of VMT release with C 3F8 gas. A study of 15 eyes (1 with 676 
MH) from Rodrigues et al.23 showed release of VMT in 60% of ey es through 6 months. Steinle 677 
et al.24 showed 83% success among 30 eyes (3 with MH) through  62 days. Finally, Chan et al.25 678 
(2017) showed 86% success among 50 eyes (15 with MH) over 9 weeks. In addition, Chan et al. 679 
reported higher rates of VMT release among eyes with MH. The release rate among eyes with 680 
VMT only in Chan et al. was 80%.25 681 
8.3.2 Sample Size Estimates  682 
Table 1 shows sample size estimates for the primary analysis under varying assumptions for the 683 
proportion of eyes with VMT release within the 2 groups. These ca lculations assume a Type I 684 
error rate of 5%, 90% power, and a two -sided test of superiority (See Section 8.6) with a null 685 
hypothesis of no difference between the groups (Section 8.2).  686 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         8-2  
   Table 1: Comparison of Proportion with VMT Release: Total Sample Size  687 
Release in PVL 
Group  Release in Sham Group  
10%  20%  30%  
50%  52 104 248 
60%  34 60 112 
70%  24 38 62 
For true outcome proportion of 60% (PVL) vs 30% (sham injection), a sample size of 112 (56 688 
per group) gives 90% power to reject the null hypothesis of no difference. Adjusting for possible 689 
loss to follow -up of 10% gives a final sample size of 124 (62 per group).  690 
8.4 Outcome Measures  691 
For the outcomes below, rescue treatment includes vitrectomy, ocriplasmin, or additional 692 
pneumatic vitreolysis du ring the course of the study.  693 
Primary Efficacy Outcome:  694 
• Proportion of eyes with central VMT release * without rescue treatment at 24 weeks.  695 
o For purposes of description only, the distribution of eyes within treatment group 696 
by the following categories at 24 weeks will be tabulated without statistical 697 
comparison:  698 
▪ Central VMT release without rescue treatment  699 
▪ Central VMT release with rescue treatment  700 
▪ No central VMT release and no rescue treatment  701 
▪ No central VMT release despite rescue treatment  702 
Secondary Efficacy Outcomes:  703 
• Proportion of eyes with central VMT release* without rescue treatment through 24 weeks 704 
(time -to-event analysis).  705 
• Proportion of eyes with central VMT release and vitreopapillary traction release* without 706 
rescue treatment at 24 we eks. 707 
• Mean change  in visual acuity letter score from baseline at 24 weeks.  708 
• Proportion of eyes with at least 10 -letter gain (increase) in visual acuity from baseline at 709 
24 weeks.  710 
• Proportion of eyes with at least 10 -letter loss (decrease) in visual acuity fro m baseline at 711 
24 weeks.  712 
• Proportion of eyes receiving rescue treatment before the 24 -week visit . 713 
o For purposes of description only, the following will be tabulated within treatment 714 
group without statistical comparison:  715 
▪ Proportion of eyes receiving rescue treatment before the 24 -week visit or 716 
for which rescue treatment is planned at the 24 -week visit and medical 717 
records confirm rescue treatment occurred within the subsequent 12 718 
weeks.  719 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         8-3  
   ▪ Type of rescue treatment.  720 
Exploratory Efficacy Outcomes:  721 
• Mean change in shape discrimination hyperacuity from baseline at 24 weeks.  722 
• Proportion of eyes with ellipsoid zone* integrity at 24 weeks.  723 
*Determined by masked grader at the central reading center.  724 
To ensure that statistical outliers do not have undue impact on  analyses of continuous outcomes, 725 
change in continuous outcomes from baseline will be truncated to ± 3 standard deviations based 726 
on the overall mean and standard deviation from both treatment groups combined at 24 weeks.  727 
8.5 Analysis Cohorts  728 
• Intention -To-Treat  (ITT) Analysis Cohort: all randomized participants irrespective of 729 
treatment received, and analyzed according to treatment assignment.  730 
• Safety Analysis Cohort: all randomized participants irrespective of treatment received, 731 
and analyzed according to treatm ent assignment.  732 
• Per-Protocol Analysis Cohort: only participants that complete the initial treatment (PVL 733 
or sham injection) and do not receive any non -protocol treatments during follow -up. 734 
Vitrectomy performed according to the criteria in section 4.2.1 is  considered per -protocol 735 
and will be included in this analysis.  736 
The primary analysis will follow the ITT principle. It will include all randomized participants. 737 
The data from the ITT cohort will be analyzed according to the group to which the participants 738 
were assigned through randomization, regardless of treatment actually received.  739 
A per -protocol analysis will be performed to provide additional information regarding the 740 
magnitude of the treatment effect. The per -protocol analysis will only be performed if  more than 741 
10% of randomized participants would be excluded by these criteria (e.g., 13 or more 742 
participants if exactly 124 are enrolled).  743 
The ITT analysis is considered the primary analysis. If the results of the per -protocol and ITT 744 
analyses give inconsi stent results, the per -protocol analysis will be interpreted with caution. In 745 
this scenario, exploratory analyses will be performed to evaluate possible factors contributing to 746 
the differences.  747 
8.6 Analysis of the Primary Efficacy Outcome  748 
The primary outcome of central VMT release without rescue treatment at 24 weeks is a binary 749 
variable that is graded by the central reading center. Logistic regression with robust variance 750 
estimation will be used to test the hypothesis of superiority (Secti on 8.2). Presence of ERM 751 
within 1 mm of the center of the macula at baseline will be included as a covariate, as previous 752 
reports have indicated the rate of VMT release differs by presence of ERM and the 753 
randomization schedules were therefore stratified by  presence of ERM. The relative risk 754 
(estimated using the method of Localio  et al.  200727) for the treatment group effect, 95% 755 
confidence interval, and P value will used to compare treatment groups. To aid in interpretation 756 
of the r elative risk, observed outcome proportions will be reported for each treatment group.  757 
Since the chance of re -attachment after release is highly unlikely before 24 weeks, an eye with 758 
central VMT release without rescue treatment prior to 24 weeks will be co nsidered to have met 759 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         8-4  
   the outcome through 24 weeks if the patient is lost to follow -up. Similarly, any eye receiving 760 
rescue treatment prior to 24 weeks will be considered not to have met the outcome through 24 761 
weeks because rescue treatment will have been g iven.  762 
Multiple imputation will be used to impute missing data for eyes lost to follow -up that did not 763 
have prior release or rescue treatment documented. The imputation model will include presence 764 
of ERM within 1 mm of the center of the macula at baseline,  treatment group, and VMT status at 765 
1, 4, 12, and 24 weeks.  766 
A sensitivity analysis will be conducted using the same approach as above but without multiple 767 
imputation (i.e., complete -case analysis).  768 
8.7 Analysis of the Secondary and Exploratory Efficacy Outcom es 769 
The ITT analysis cohort will be used for all secondary and exploratory outcomes.  770 
8.7.1. Secondary Efficacy Outcomes  771 
Development of central VMT release without rescue treatment through 24 weeks is a time -to- 772 
event outcome that will be modeled with Cox pro portional hazards regression and robust 773 
variance estimation. The hazard ratio along with the 95% confidence interval and P value will be 774 
used to compare treatment groups. To aid in interpretation, a Kaplan -Meier plot will be 775 
constructed. Data from eyes not  observed to have release or that receive rescue treatment will be 776 
censored on the date of their final visit.  777 
The proportion of eyes with central VMT release and vitreopapillary traction release (without 778 
rescue treatment) at 24 weeks is a binary variable g raded by the central reading center that will 779 
be analyzed with logistic regression. Analysis and imputation of missing data will be handled in 780 
a manner similar to the primary outcome. The analysis will be adjusted for vitreopapillary 781 
traction status at bas eline.  782 
Change in visual acuity letter score from baseline to 24 weeks is a continuous variable that will 783 
be analyzed using a general linear model with robust variance estimation. Presence of ERM 784 
within 1 mm of the center of the macula at baseline and baseline visual acuity will be included as 785 
covariates. The treatment group difference, 95% confidence interval, and P value will be 786 
presented. To aid in interpretation, least squares means and associated 95% confidence intervals 787 
for each gr oup will used to compare treatment groups. Serious violations of statistical 788 
assumptions may be addressed by transformation of variables, non -parametric methods, or 789 
categorizing continuous covariates. Missing data will be imputed with multiple imputation. The 790 
imputation model will include presence of ERM within 1 mm of the center of the macula  at 791 
baseline, treatment group, baseline visual acuity, and change in visual acuity from baseline at 1, 792 
4, 12, and 24 weeks, and VMT status at 1, 4, 12, and 24 weeks.  793 
The proportion of eyes with at least 10 -letter gain (increase) or loss (decrease) in visual acuity 794 
from baseline are binary variables that will be analyzed with logistic regression and will use the 795 
imputed data sets from the analysis of mean change in visu al acuity from baseline.  796 
The proportion of eyes receiving rescue treatment before the 24 -week visit is a binary variable 797 
that will be analyzed with logistic regression. The presence of ERM within 1 mm of the center of 798 
the macula at baseline will be include d as a covariate.  Complete -case analysis (no imputation of 799 
missing data) will be used for this outcome.  800 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         8-5  
   8.7.2 Exploratory Efficacy Outcomes  801 
Change in shape discrimination hyperacuity  (measured in logMAR) is a continuous variable that 802 
will be analyzed as ab ove but substituting baseline and follow -up shape discrimination 803 
hyperacuity  for visual acuity. Complete -case analysis (no imputation of missing data) will be 804 
used for this outcome.  805 
The proportion of eyes with ellipsoid integrity  at 24 weeks is a binary va riable graded by the 806 
central reading center (loss of integrity and no loss of integrity). Logistic regression adjusted for 807 
ellipsoid zone status at baseline and the  presence of ERM within 1 mm of the center of the 808 
macula at baseline will be used to compare  treatment groups. The relative risk for the treatment 809 
group effect, 95% confidence interval, and P value will used to compare treatment groups. To 810 
aid in interpretation of the relative risk, observed outcome proportions will be reported for each 811 
treatment  group. Complete -case analysis (no imputation of missing data) will be used for this 812 
outcome.  813 
8.8 Safety Analyses  814 
All reportable adverse events will be categorized as study eye or systemic. All events will be 815 
tabulated by treatment group in a listing of each r eported Medical Dictionary for Regulatory 816 
Activities (MedDRA) term and summarized over each MedDRA System Organ Class. All 817 
randomized participants will be included in safety analyses. Any events occurring between 818 
randomization and study treatment will be n oted.  819 
8.8.1 Ocular Adverse Events  820 
The frequency of each ocular adverse event occurring at least once per eye will be calculated. 821 
The proportion of eyes experiencing each outcome will be compared between treatment groups 822 
with Barnard’s unconditional exact test. The following ocular adverse events are of primary 823 
interest:  824 
o Retinal detachment  825 
o Retinal tear  826 
o Macular hole development  827 
o Cataract extraction in eyes phakic at baseline  828 
o Vitreous hemorrhage  829 
o Adverse IOP events (composite outcome)  830 
▪ Increase in IOP ≥ 10 mmHg from baseline (at a follow -up visit)  831 
▪ IOP ≥ 30 mmHg (at a follow -up visit)  832 
▪ Initiation of medication to lower IOP that was not in use at baseline  833 
▪ Glaucoma procedure  834 
The number of eyes with endophthalmitis and traumatic cataract will be tabulated without 835 
statistical comparison.  836 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         8-6  
   8.8.2 Systemic Adverse Events  837 
The frequency of each systemic adverse event occurring at least once per participant will be 838 
calculated. The proportion of participants experiencing each outcome will be compared with 839 
Barnard’s unconditional exac t test. The following systemic adverse events are of primary 840 
interest:  841 
o Death  842 
o Serious adverse event (at least one)  843 
The following systemic adverse events are of secondary interest and will be tabulated without 844 
statistical comparison:  845 
o For each MedDRA System Organ Class, proportion of participants with at least one 846 
serious event  847 
For each treatment group, the number of adverse events (ocular or systemic) considered related 848 
to treatment will be tabulated.  849 
8.9 Intervention Adherence  850 
Adherence will be defined as completion of the treatment assigned at randomization, either PVL 851 
or sham injection.  852 
8.10 Protocol Adherence and Retention  853 
Protocol deviations and visit completion rates (excluding deaths) will be tabulated for each 854 
treatment group.  855 
8.11 Baseline Descriptive Stat istics  856 
Baseline characteristics will be tabulated by treatment group and summary statistics appropriate 857 
to the distribution will be reported.  858 
8.12 Planned Interim Analyses  859 
There is no formal interim analysis planned for this study. The Data and Safety Monitory 860 
Committee (DSMC) will review safety and outcome data approximately every 6 months while 861 
the study is ongoing.  862 
8.13 Subgroup Analyses  863 
Subgroup analyses, i.e., assessments of effect modification (interaction), will be conducted for 864 
the primary outcome. These anal yses will be considered exploratory. Additionally, interpretation 865 
of the analyses will depend on whether the primary analysis demonstrates a significant treatment 866 
group difference; in the absence of such a difference, subgroup analyses will be interpreted with 867 
caution.  868 
The general approach for these exploratory analyses will be to add an interaction term for the 869 
subgroup factor by treatment into the primary analysis model. In addition, within -subgroup 870 
treatment effects and 95% confidence intervals will be estimated from the interaction model if 871 
the interaction  P value is less than .05. Subgroup analyses will use data from eyes that complete 872 
the 24 -week visit or have VMT release  or rescue treatment prior to 24 weeks (i.e., complete case 873 
analysis as described  in section 8.6).  874 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         8-7  
   The primary subgroup analysis will evaluate the effect of ERM presence within 1 mm of the 875 
center of the macula. In previous studies, eyes with ERM treated with C 3F8 for VMT had lower 876 
release rates compared with eyes not having ERM.10, 11, 25 It is unknown what effect ERM may 877 
have on the release rate in the observation group.  878 
Secondary subgroup analyses will include ERM presence at the site of vitreous adhesion, lens 879 
status (phakic or pseudophakic), components of VMT severity grade,6 length of adhesion on 880 
OCT (less than or equal to 1500 microns or greater than 1500 microns), and diabetes status (has 881 
diabetes or does not have diabetes).  882 
There are no data to suggest that the treatment effect will vary by sex or race/ethnicity. However, 883 
both of these factors will be evaluated in exploratory subgroup analyses as mandated by National 884 
Institutes of Health (NIH) guidelines.  885 
Subgroup factors wi ll be analyzed as categorical and continuous or ordinal variables where 886 
possible. Secondary and exploratory subgroup analyses will only be conducted if there are at 887 
least 20 eyes in each subgroup for each treatment group.  888 
8.14 Multiple Testing  889 
There will be no formal adjustment for multiple testing. Only P ≤ .05 will be considered of 890 
interest.  891 
8.15 Assessment of Confounding  892 
Imbalances between groups in important covariates are not expected to be of sufficient 893 
magnitude to produce confounding. How ever, a sensitivity analysis using observed data (no 894 
multiple imputation) will be conducted if there is an imbalance between treatment groups in any 895 
of the following: presence of ERM, lens status, extent of VMT, diabetes status, age, or sex. 896 
Imbalance by t reatment group will not be judged using statistical testing. Instead, imbalance will 897 
be judged by whether the imbalance is large enough to have a clinically important effect on the 898 
primary outcome.  The sensitivity analysis will mimic the primary analysis b ut add any 899 
potentially imbalanced factors as covariates. 900 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         9-1  
   CHAPTER 9:  DATA COLLECTION  AND MONITORING  901 
9.1 Case Report Forms and Device Data  902 
The main study data are collected through electronic case report forms (CRFs) . These electronic 903 
CRFs from the study website are considered the primary source documentation.  904 
Each participating site will maintain appropriate medical and research records for this trial, in 905 
compliance with ICH E6 and regulatory and institutional requirements for the protection of 906 
confidentiality of par ticipants.  907 
9.2 Study Records Retention  908 
Study documents should be retained for a minimum of 3 years following the NIH grant cycle for 909 
which the last visit was completed (expected to be December 31, 2026) . These documents should 910 
be retained for a longer period, however, if required by local regulations . No records will be 911 
destroyed without the written consent of JCHR .  912 
9.3 Quality Assurance and Monitoring  913 
Designated personnel from the Coordinating Center will be responsible for maintaining quality 914 
assurance (QA) and quality control (QC) systems to ensure that the clinical portion of the trial is 915 
conducted and data are generated, documented and reported in compliance with the protocol, 916 
Good Clinical Practice (GCP) and the applicable regulatory requirements . Adverse eve nts will be 917 
prioritized for monitoring.  918 
A risk -based monitoring (RBM) plan will be developed and revised as needed during the course 919 
of the study, consistent with the FDA “Guidance for Industry Oversight of Clinical 920 
Investigations — A Risk -Based Approach t o Monitoring” (August 2013) . Study conduct and 921 
monitoring will conform with 21 Code of Federal Regulations (CFR) 812.  922 
The most important  data for monitoring at the site are participant eligibility and adverse events . 923 
Therefore, the RBM plan will focus on t hese areas . As much as possible, remote monitoring will 924 
be performed in real -time with on -site monitoring performed to evaluate the verity and 925 
completeness of the key site data . Elements of the RBM may include:  926 
• Qualification assessment, training, and certi fication for sites and site personnel  927 
• Oversight of Institutional Review Board (IRB) coverage and informed consent 928 
procedures  929 
• Central (remote) data monitoring: validation of data entry, data edits/audit trail, protocol 930 
review of entered data and edits, stat istical monitoring, study closeout  931 
• On-site monitoring (site visits): source data verification, site visit report  932 
• Communications with site staff  933 
• Patient retention and visit completion  934 
• Quality control reports  935 
• Management of noncompliance  936 
• Documenting monitorin g activities  937 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         9-2  
   • Adverse event reporting and monitoring  938 
Coordinating Center representatives or their designees may visit the study facilities at any time in 939 
order to maintain current and personal knowledge of the study through review of the records, 940 
comparison  with source documents, observation and discussion of the conduct and progress of 941 
the study.  942 
9.4 Protocol Deviations  943 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure 944 
requirements . The noncompliance may be either on the part of the participant, the investigator, or 945 
the study site staff . As a result of deviations, corrective actions are to be developed by the site 946 
and implemented promptly.  947 
The site principal investigator  and study staff are responsible for knowing and adhering to their 948 
IRB requirements . Further details about the handling of protocol deviations will be included in 949 
the monitoring plan.  950 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         10-1  
   CHAPTER 10:  ETHICS/PROTECTION OF HUMAN PARTICIPANTS  951 
10.1 Ethical Standard  952 
The principal  investigator will ensure that this study is conducted in full conformity with 953 
Regulations for the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 954 
CFR Part 50, 21 CFR Part 56, and/or the ICH E6.  955 
10.2 Institutional Review Boards  956 
The p rotocol, informed consent form(s), recruitment materials, and all participant materials will 957 
be submitted to the IRB for review and approval . Approval of both the protocol and the consent 958 
form must be obtained before any participant is enrolled . Any amendment to the protocol will 959 
require review and approval by the IRB before the changes are implemented to the study . All 960 
changes to the consent form will be IRB approved; a determination will be made regarding 961 
whether previously consented participants ne ed to be re -consented.  962 
10.3 Informed Consent Process  963 
10.3.1  Consent Procedures and Documentation  964 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 965 
the study and continues throughout the individual’s study participatio n. Extensive discussion of 966 
risks and possible benefits of participation will be provided to the participants and their families . 967 
Consent forms will be IRB -approved and the participant will be asked to read and review the 968 
document . The investigator will exp lain the research study to the participant and answer any 969 
questions that may arise . All participants will receive a verbal explanation in terms suited to their 970 
comprehension of the purposes, procedures, and potential risks of the study and of their rights as 971 
research participants . Participants will have the opportunity to carefully review the written 972 
consent form and ask questions prior to signing.  973 
The participants should have the opportunity to discuss the study with their surrogates or think 974 
about it prio r to agreeing to participate . The participant will sign the informed consent document 975 
prior to any procedures being done specifically for the study . The participants may withdraw 976 
consent at any time throughout the course of the trial . A copy of the informe d consent document 977 
will be given to the participants for their records . The rights and welfare of the participants will 978 
be protected by emphasizing to them that the quality of their medical care will not be adversely 979 
affected if they decline to participate  in this study.  980 
10.3.2  Participant and Data C onfidentiality  981 
Participant confidentiality is strictly held in trust by the participating investigators, their staff, 982 
and the JCHR  and their agents . This confidentiality is extended to cover biological samples  in 983 
addit ion to the clinical information relating to participants . Therefore, the study protocol, 984 
documentation, data, and all other information generated will be held in strict confidence . No 985 
information concerning the study or the data will be released to any una uthorized third party 986 
without prior written approval of the JCHR . 987 
The study monitor, other authorized representatives of the JCHR , or representatives of the IRB 988 
may inspect all documents and records required to be maintained by the investigator, including 989 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         10-2  
   but not limited to, medical records (office, clinic, or hospital) and pharmacy records for the 990 
participants in this study . The clinical study site will permit access to such records.  991 
The study participant’s contact information will be securely stored at ea ch clinical site for 992 
internal use during the study . At the end of the study, all records will continue to be kept in a 993 
secure location for as long a period as dictated by local IRB and institutional  regulations.  994 
Study participant research data, which is fo r purposes of statistical analysis and scientific 995 
reporting, will be transmitted to and stored at the coordinating center, the Jaeb Center for Health 996 
Research (JCHR) in Tampa, FL . This will not include the participant’s contact or identifying 997 
information . Rather, individual participants and their research data will be identified by a unique 998 
study identification number . The study data entry and study management systems used by 999 
clinical sites and by JCHR  research staff will be secured and password protected . At the end of 1000  
the study, all study databases will be de -identified and archived at JCHR . 1001  
10.3.3  Future Use of Stored Specimens  1002  
With the participant’s approval, de -identified biological samples will be stored at a central 1003  
repository  for future research into the causes , complications, and treatments  of retinal diseases . 1004  
The repository will also be provided with a code -link that will allow linking the biological 1005  
specimens with the phenotypic data from each participant, maintaining the masking of the 1006  
identity of the  participant.  1007  
During the conduct of the study, an individual participant can choose to withdraw consent to 1008  
have biological specimens stored for future research . However, withdrawal of consent with 1009  
regard to biosample storage will not be possible after the study is completed.  1010  
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         11-1  
   CHAPTER 11:  REFERENCES  1011  
 1012  
1. Jackson TL, Nicod E, Simpson A, Angelis A, Grimaccia F, Kanavos P. Symptomatic 1013  
vitreomacular adhesion. Retina.  2013;33(8):1503 -11. 1014  
2. Duker JS, Kaiser PK, Binder S, et al. The International Vitreomacular Traction Study 1015  
Group classification of vitreomacular  adhesion, traction, and macular hole. 1016  
Ophthalmology.  2013;120(12):2611 -9. 1017  
3. Almeida DR, Chin EK. Spontaneous resolution of vitreomacular traction in two patients 1018  
with diabetic macular edema. Case Rep Ophthalmol.  2014;5(1):66 -71. 1019  
4. Dimopoulos S, Bartz -Schmidt KU, Gelisken F, Januschowski K, Ziemssen F. Rate and 1020  
timing of spontaneous resolution in a vitreomacular traction group: should the role of 1021  
watchful waiting be re -evaluated as an alternative to ocriplasmin therapy? Br J 1022  
Ophthalmol.  2015;99(3):350 -3. 1023  
5. Hwang DJ, Park KH, Woo SJ. Spontaneous resolution of vitreomacular traction 1024  
syndrome with persistent vitreofoveal adhesion observed on spectral -domain optical 1025  
coherence tomography. Can J Ophthalmol.  2012;47(5):e17 -9. 1026  
6. John VJ, Flynn HW, Jr., Smiddy WE , et al. Clinical course of vitreomacular adhesion 1027  
managed by initial observation. Retina.  2014;34(3):442 -6. 1028  
7. Theodossiadis GP, Grigoropoulos VG, Theodoropoulou S, Datseris I, Theodossiadis PG. 1029  
Spontaneous resolution of vitreomacular traction demonstrate d by spectral -domain 1030  
optical coherence tomography. Am J Ophthalmol.  2014;157(4):842 -51 e1.  1031  
8. Tzu JH, John VJ, Flynn HW, Jr., et al. Clinical Course of Vitreomacular Traction 1032  
Managed Initially by Observation. Ophthalmic Surg Lasers Imaging Retina.  1033  
2015;46( 5):571 -6. 1034  
9. Neffendorf JE, Kirthi V, Pringle E, Jackson TL. Ocriplasmin for symptomatic 1035  
vitreomacular adhesion. Cochrane Database Syst Rev.  2017;10:CD011874.  1036  
10. Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for 1037  
vitreomac ular traction and macular holes. N Engl J Med.  2012;367(7):606 -15. 1038  
11. Dugel PU, Tolentino M, Feiner L, Kozma P, Leroy A. Results of the 2 -Year Ocriplasmin 1039  
for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole 1040  
(OASIS) Randomized Trial. Ophthalmology.  2016;123(10):2232 -47. 1041  
12. Stefanini FR, Maia M, Falabe lla P, et al. Profile of ocriplasmin and its potential in the 1042  
treatment of vitreomacular adhesion. Clin Ophthalmol.  2014;8:847 -56. 1043  
13. Lim J, Glassman A, Aiello L, et al. Macula Society collaborative retrospective study of 1044  
ocriplasmin for symptomatic vitre omacular adhesion. Ophthal Retina.  2017;1(5):413 -20. 1045  
14. Fahim AT, Khan NW, Johnson MW. Acute panretinal structural and functional 1046  
abnormalities after intravitreous ocriplasmin injection. JAMA Ophthalmol.  1047  
2014;132(4):484 -6. 1048  
15. Freund KB, Shah SA, Shah VP.  Correlation of transient vision loss with outer retinal 1049  
disruption following intravitreal ocriplasmin. Eye (Lond).  2013;27(6):773 -4. 1050  
16. Hager A, Seibel I, Riechardt A, Rehak M, Joussen AM. Does ocriplasmin affect the RPE - 1051  
photoreceptor adhesion in macular  holes? Br J Ophthalmol.  2015;99(5):635 -8. 1052  
17. Kim JE. Safety and complications of ocriplasmin: ocriplasmin, ocriplasmin; oh, how safe 1053  
art thou? JAMA Ophthalmol.  2014;132(4):379 -80. 1054  
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         11-2  
   18. Tibbetts MD, Reichel E, Witkin AJ. Vision loss after intravitreal ocri plasmin: correlation 1055  
of spectral -domain optical coherence tomography and electroretinography. JAMA 1056  
Ophthalmol.  2014;132(4):487 -90. 1057  
19. American Society of Retina Specialists Preference and Trends (PAT) Survey 2017, 1058  
accessed at  www.asrs.org/asrs -commu nity/pat -survey . 1059  
20. Chan CK, Wessels IF, Friedrichsen EJ. Treatment of idiopathic macular holes by induced 1060  
posterior vitreous detachment. Ophthalmology.  1995;102(5):757 -67. 1061  
21. Costa RA, Cardillo JA,  Morales PH, Jorge R, Uno F, Farah ME. Optical coherence 1062  
tomography evaluation of idiopathic macular hole treatment by gas -assisted posterior 1063  
vitreous detachment. Am J Ophthalmol.  2001;132(2):264 -6. 1064  
22. Jorge R, Costa RA, Cardillo JA, Uno F, Bonomo PP, Far ah ME. Optical coherence 1065  
tomography evaluation of idiopathic macular hole treatment by gas -assisted posterior 1066  
vitreous detachment. Am J Ophthalmol.  2006;142(5):869 -71. 1067  
23. Rodrigues IA, Stangos AN, McHugh DA, Jackson TL. Intravitreal injection of expansile  1068  
perfluoropropane (c(3)f(8)) for the treatment of vitreomacular traction. Am J Ophthalmol.  1069  
2013;155(2):270 -6 e2.  1070  
24. Steinle NC, Dhoot DS, Quezada Ruiz C, et al. Treatment of Vitreomacular Traction with 1071  
Intravitreal Perfluoropropane (C3f8) Injection. Retin a. 2017;37(4):643 -50. 1072  
25. Chan CK, Crosson JN, Mein CE, Daher N. Pneumatic Vitreolysis for Relief of 1073  
Vitreomacular Traction. Retina.  2017.  1074  
26. Chan C. Pneumatic Vitreolysis for Resolving Focal Vitreomacular Traction: An Update 1075  
on Clinical Outcome . 2019 Re tina Society, 52nd Scientific Program, Landmark Hotel, 1076  
London, UK, Sept 11 to 15, 2019.  1077  
27. Localio AR, Margolis DJ, Berlin JA. Relative risks and confidence intervals were easily 1078  
computed indirectly from multivariable logistic regression. J Clin Epidemiol . 1079  
2007;60(9):874 -82. 1080  
 1081  